NASDAQ:BPMC

Blueprint Medicines (BPMC) Stock Forecast, Price & News

$50.22

-0.85 (-1.66%)

(As of 09/29/2023 ET)

Compare

Today's Range: $49.91
▼
$52.02
50-Day Range: $46.90
▼
$66.00
52-Week Range: $37.82
▼
$68.63

Volume: 730,247 shs
Average Volume: 600,163 shs
Market Capitalization: $3.05 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $75.21

Blueprint Medicines MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 49.8% Upside
$75.21 Price Target
Short Interest: Bearish
6.86% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.04
Based on 6 Articles This Week
Insider Trading: Selling Shares
$847,673 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($9.06) to ($7.52) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

501st out of 973 stocks

Pharmaceutical Preparations Industry

236th out of 450 stocks

4.3

Analyst's Opinion

Consensus Rating
Blueprint Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 3 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $75.21, Blueprint Medicines has a forecasted upside of 49.8% from its current price of $50.22.
Amount of Analyst Coverage
Blueprint Medicines has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
6.86% of the outstanding shares of Blueprint Medicines have been sold short.
Short Interest Ratio / Days to Cover
Blueprint Medicines has a short interest ratio ("days to cover") of 6.8.
Change versus previous month
Short interest in Blueprint Medicines has recently increased by 1.71%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Blueprint Medicines does not currently pay a dividend.
Dividend Growth
Blueprint Medicines does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BPMC.

3.4

News and Social Media Coverage

News Sentiment
Blueprint Medicines has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Blueprint Medicines this week, compared to 4 articles on an average week.
Search Interest
Only 3 people have searched for BPMC on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
1 people have added Blueprint Medicines to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $847,673.00 in company stock.
Percentage Held by Insiders
Only 3.88% of the stock of Blueprint Medicines is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Blueprint Medicines are expected to grow in the coming year, from ($9.06) to ($7.52) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Blueprint Medicines is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Blueprint Medicines is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Blueprint Medicines has a P/B Ratio of 5.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Blueprint Medicines (NASDAQ:BPMC) Stock

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

BPMC Price History

30 days | 90 days | 365 days | Advanced Chart

BPMC Stock News Headlines

September 23, 2023 | americanbankingnews.com

Zacks Research Weighs in on Blueprint Medicines Co.'s Q1 2024 Earnings (NASDAQ:BPMC)

September 13, 2023 | markets.businessinsider.com

Berenberg Bank Sticks to Their Buy Rating for Blueprint Medicines (BPMC)

September 29, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

September 8, 2023 | finance.yahoo.com

Deciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound?

September 1, 2023 | finance.yahoo.com

Why Is Blueprint Medicines (BPMC) Down 2% Since Last Earnings Report?

August 3, 2023 | seekingalpha.com

Blueprint Medicines: Rating Downgrade Amid Growth Concerns

August 3, 2023 | markets.businessinsider.com

What 15 Analyst Ratings Have To Say About Blueprint Medicines

August 3, 2023 | msn.com

Blueprint Medicines dips despite Q2 beat

September 29, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

August 3, 2023 | markets.businessinsider.com

Blueprint Medicines (BPMC) Gets a Buy from H.C. Wainwright

August 2, 2023 | finance.yahoo.com

Blueprint Medicines (BPMC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

August 2, 2023 | finance.yahoo.com

Why Shares of Blueprint Medicines Are Falling Wednesday

August 2, 2023 | seekingalpha.com

Blueprint Medicines Corporation 2023 Q2 - Results - Earnings Call Presentation

August 2, 2023 | finanznachrichten.de

Blueprint Medicines Corporation: Blueprint Medicines Reports Second Quarter 2023 Results

August 2, 2023 | finance.yahoo.com

Blueprint Medicines Reports Second Quarter 2023 Results

July 31, 2023 | msn.com

Wells Fargo Upgrades Blueprint Medicines (BPMC)

July 19, 2023 | finance.yahoo.com

Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023

July 14, 2023 | msn.com

Morgan Stanley Reiterates Blueprint Medicines (BPMC) Equal-Weight Recommendation

July 5, 2023 | fool.com

Blueprint Medicines (NASDAQ: BPMC)

June 30, 2023 | reuters.com

Genentech withdraws use of Gavreto in US for a type of thyroid cancer, says partner Blueprint

June 30, 2023 | finance.yahoo.com

UPDATE 1-Genentech withdraws use of Gavreto in US for a type of thyroid cancer, says partner Blueprint

June 26, 2023 | finance.yahoo.com

3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon

June 9, 2023 | finance.yahoo.com

Blueprint Medicines (NASDAQ:BPMC) investors are sitting on a loss of 24% if they invested five years ago

June 8, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Blueprint Medicines (BPMC) and Relay Therapeutics (RLAY)

June 5, 2023 | msn.com

SVB Leerink Downgrades Blueprint Medicines (BPMC)

June 5, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Blueprint Medicines (BPMC) and Taro Pharmaceutical (TARO)

June 4, 2023 | finance.yahoo.com

This Biotech Could Soon Go Parabolic, But Should You Buy It?

See More Headlines

Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Company Calendar

Last Earnings: 8/02/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BPMC
CUSIP: N/A
CIK: 1597264
Web: www.blueprintmedicines.com
Phone: (617) 374-7580
Fax: N/A
Employees: 660
Year Founded: 2011

Price Target and Rating

Average Stock Price Forecast: $75.21
High Stock Price Forecast: $114.00
Low Stock Price Forecast: $38.00
Forecasted Upside/Downside: +49.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($9.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-557,520,000.00
Net Margins: -245.62%
Pretax Margin: -244.46%
Return on Equity: -117.88%
Return on Assets: -43.17%

Debt

Debt-to-Equity Ratio: 0.39
Current Ratio: 4.80
Quick Ratio: 4.70

Sales & Book Value

Annual Sales: $204.04 million
Price / Sales: 15.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.60 per share
Price / Book: 5.87

Miscellaneous

Outstanding Shares: 60,670,000
Free Float: 58,311,000
Market Cap: $3.06 billion
Optionable: Optionable
Beta: 0.74

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Ms. Kathryn Haviland (Age 47)
Pres, CEO & Director
Comp: $1.17M

Mr. Alexis A. Borisy A.M. (Age 51)
Co-Founder & Director
Comp: $50k

Mr. Michael Landsittel (Age 51)
Chief Financial Officer
Comp: $785.36k

Ms. Christina Rossi (Age 46)
Chief Operating Officer
Comp: $875.22k

Ms. Tracey L. McCain Esq. (Age 55)
Exec. VP, Chief Legal & Compliance Officer and Sec.
Comp: $764.9k

Dr. Fouad Namouni M.D. (Age 54)
Pres of R&D
Comp: $916.4k

Ms. Ariel Hurley (Age 49)
Sr. VP, Fin. & Principal Accounting Officer

Dr. Christopher K. Murray Ph.D. (Age 59)
Sr. VP of Technical Operations and Chief Technical Operations & Quality Officer

Dr. Percy H. Carter M.B.A. (Age 52)
Ph.D., Chief Scientific Officer

Jenna Cohen
Sr. Director & Head of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BPMC Stock - Frequently Asked Questions

Should I buy or sell Blueprint Medicines stock right now?: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 2 sell ratings, 3 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BPMC shares.
View BPMC analyst ratings or view top-rated stocks.
What is Blueprint Medicines' stock price forecast for 2023?: 12 equities research analysts have issued 1 year target prices for Blueprint Medicines' shares. Their BPMC share price forecasts range from $38.00 to $114.00. On average, they expect the company's stock price to reach $75.21 in the next twelve months. This suggests a possible upside of 49.1% from the stock's current price.
View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts.
How have BPMC shares performed in 2023?: Blueprint Medicines' stock was trading at $43.81 at the beginning of the year. Since then, BPMC stock has increased by 15.2% and is now trading at $50.45.
View the best growth stocks for 2023 here.
When is Blueprint Medicines' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our BPMC earnings forecast.
How were Blueprint Medicines' earnings last quarter?: Blueprint Medicines Co. (NASDAQ:BPMC) announced its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($2.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.58) by $0.39. The biotechnology company had revenue of $57.60 million for the quarter, compared to analysts' expectations of $45.60 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 117.88% and a negative net margin of 245.62%. Blueprint Medicines's revenue for the quarter was up 57.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.68) earnings per share.
What ETFs hold Blueprint Medicines' stock?: ETFs with the largest weight of Blueprint Medicines (NASDAQ:BPMC) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), Fidelity Disruptive Medicine ETF (FMED), Harbor Corporate Culture Small Cap ETF (HAPS), BlackRock Future Health ETF (BMED) and Principal Healthcare Innovators ETF (BTEC).
What is Kate Haviland's approval rating as Blueprint Medicines' CEO?: 16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

What other stocks do shareholders of Blueprint Medicines own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).
When did Blueprint Medicines IPO?: (BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
What is Blueprint Medicines' stock symbol?: Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."
How do I buy shares of Blueprint Medicines?: Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Blueprint Medicines' stock price today?: One share of BPMC stock can currently be purchased for approximately $50.45.
How much money does Blueprint Medicines make?: Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $3.06 billion and generates $204.04 million in revenue each year. The biotechnology company earns $-557,520,000.00 in net income (profit) each year or ($9.22) on an earnings per share basis.
How many employees does Blueprint Medicines have?: The company employs 660 workers across the globe.
How can I contact Blueprint Medicines?: Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com.

This page (NASDAQ:BPMC) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Blueprint Medicines (BPMC) Stock Forecast, Price & News

Blueprint Medicines MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Blueprint Medicines (NASDAQ:BPMC) Stock

BPMC Price History

BPMC Stock News Headlines

BPMC Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

BPMC Stock - Frequently Asked Questions

Overall MarketRank^™